Published in J Clin Pathol on June 25, 2012
Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol (2013) 1.04
Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal Dis (2014) 1.00
Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer (2014) 1.00
Controversies in the pathological assessment of colorectal cancer. World J Gastroenterol (2014) 0.92
Pathological grading of regression: an International Study Group perspective. J Clin Pathol (2012) 0.87
Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int J Cancer (2015) 0.78
MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. Int J Mol Sci (2016) 0.78
Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol (2016) 0.76
Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system. J Gastrointest Oncol (2017) 0.75
Utility of rectoscopy in the assessment of response to neoadjuvant treatment for locally advanced rectal cancer. Saudi J Gastroenterol (2016) 0.75
Predictive Response Value of Pre- and Postchemoradiotherapy Variables in Rectal Cancer: An Analysis of Histological Data. Patholog Res Int (2016) 0.75
Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery? World J Gastroenterol (2017) 0.75
Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis. Int J Clin Exp Pathol (2015) 0.75
Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers. Ann R Coll Surg Engl (2017) 0.75
Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy. Int J Colorectal Dis (2016) 0.75
DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys (2007) 3.65
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal (2008) 1.99
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev (2005) 1.83
Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2002) 1.69
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res (2010) 1.64
Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. EMBO J (2009) 1.41
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res (2010) 1.29
Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol (2009) 1.24
Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol (2012) 0.93
Biological and therapeutic relevance of nonreplicative DNA polymerases to cancer. Antioxid Redox Signal (2012) 0.89
Simultaneous determination of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA using online column-switching liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2009) 0.88
Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) (2014) 0.85
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? Crit Rev Oncol Hematol (2012) 0.83
The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol (2003) 0.82
Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. Cancer Lett (2007) 0.80
Homologous recombination mediates S-phase-dependent radioresistance in cells deficient in DNA polymerase eta. Carcinogenesis (2012) 0.80
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. Int J Cancer (2013) 0.79
Intra-arterial brachytherapy of hepatic malignancies: watch the flow. Nat Rev Clin Oncol (2010) 0.78
Biological relevance of DNA polymerase β and translesion synthesis polymerases to cancer and its treatment. Curr Mol Pharmacol (2012) 0.77
Cancer prevention and delay are as important as cure. Lancet Oncol (2003) 0.75
Will the medical student in the team please stand up? Lancet Oncol (2012) 0.75